Case Reports in Neurological Medicine

Case Reports in Neurological Medicine / 2017 / Article

Case Report | Open Access

Volume 2017 |Article ID 2834349 |

Jin Kyo Choi, Jin Yong Hong, "Acute Cervical Dystonia Induced by Clebopride", Case Reports in Neurological Medicine, vol. 2017, Article ID 2834349, 2 pages, 2017.

Acute Cervical Dystonia Induced by Clebopride

Academic Editor: Isabella Laura Simone
Received29 Sep 2017
Accepted05 Nov 2017
Published28 Nov 2017


Antidopaminergic drugs are known to induce extrapyramidal symptoms. Clebopride, a dopamine antagonist, also can produce parkinsonism, tardive dyskinesia, tardive dystonia, hemifacial dystonia, or oculogyric crisis; however, acute dystonic reaction caused by clebopride has not been reported in adults. We report two young men who experienced acute cervical dystonia within a few days of taking clebopride. The patients recovered after discontinuation of the drug. Physicians prescribing clebopride should be aware of the adverse effects of this drug.

1. Introduction

Extrapyramidal symptoms can be induced by many agents. Antiemetics are widely used to treat patients with gastrointestinal problems; however, their antidopaminergic effect makes them the most common cause of drug-induced movement disorders [1]. Clebopride, a nonselective benzamide, also has high affinity for D2, D3, and D4 receptors [2]; thus, it acts as a dopamine receptor-blocking agent. Although parkinsonism [3, 4], tardive dyskinesia [4], tardive dystonia [5, 6], hemifacial dystonia [7], and oculogyric crisis [8] have been reported to be caused by clebopride, acute cervical dystonia has not been observed in adults treated with this drug. Here, we present two young men who presented with acute cervical dystonia related to the administration of clebopride.

2. Case Presentation

2.1. Case  1

A 26-year-old man visited our hospital for stiffness and pain in the neck that had persisted for one day. He felt spasms and twisting of the neck the day before visiting our hospital and reported that intravenous injection of diazepam in another hospital was ineffective. A physical examination showed increased tone in all muscles of the neck and a dystonic posture with torticollis to the left side (video). However, no neurological abnormality including dysarthria, motor weakness, sensory change, ataxia, bradykinesia, or tremor was found. He had taken clebopride (680 μg, three times a day), simethicone (200 mg, three times a day), tiropramide (100 mg, three times a day), ranitidine (150 mg, three times a day), almagate (500 mg, three times a day), and pantoprazole (10 mg, once a day) for reflex esophagitis for 7 days before developing dystonia. There was no other drug before treatment for reflex esophagitis. Brain magnetic resonance imaging (MRI) results were normal and there was no mutation in either DYT1 or PANK2 genes. Results of other laboratory tests including those for serum copper, total urine copper during 24 hours, serum ceruloplasmin, and serum ferritin were also within normal ranges.

The patient discontinued taking the drugs on the visit day, and then we prescribed clonazepam (0.25 mg, twice a day), eperisone (50 mg, twice a day), and benztropine (1 mg, twice a day) for symptom relief. Dystonia remitted completely 7 days after the change in medications and did not recur after the symptomatic treatment was stopped.

2.2. Case  2

An 18-year-old man visited our emergency department for neck pain and spasm. The symptom developed suddenly 2 hours before the visit. Physical examination showed increased muscle tone and dystonic posture of the neck, but there was no neurological abnormality such as bradykinesia, ataxia, motor weakness, or hypoesthesia. He had taken clebopride (680 μg, three times a day), simethicone (200 mg, three times a day), and tiropramide (100 mg, three times a day) for nausea and vomiting for 2 days before the appearance of dystonia. He had neither medicosurgical history nor oral medication before the gastric symptom. Results of brain MRI and routine serologic study were normal.

The patient stopped clebopride and was started on baclofen (5 mg, three times a day). Dystonic symptoms disappeared within 5 days and did not recur after discontinuation of baclofen.

3. Discussion

To our knowledge, this is the first report of acute cervical dystonia induced by clebopride in adults. Clebopride has been reported to cause acute events as hypertonic reaction in children [9] and oculogyric crisis in young adults [8], but only one case of acute hemifacial dystonia was observed in adults [7]. Other extrapyramidal symptoms that developed in adults were chronic reactions including parkinsonism [3, 4] or tardive dyskinesia [4].

In our patients, cervical dystonia developed within a few days of clebopride use. Therefore, it can be classified as an acute dystonic reaction (ADR). About 50% of the cases of ADR occur within 48 hours and 90% within 5 days of drug treatment [10]. ADR is induced mainly by antipsychotics [11], but diverse drugs including fluoxetine [12], domperidone [13], and metoclopramide [14, 15] can cause it. Young age, higher potency and dose of the offending drug, and psychiatric illness are known risk factors for ADR [15]. Similar to children and young adults showing ADR in the previous report [8, 9, 15], our patients were also young. Therefore, ADR may be related to maturity or activity of the dopaminergic system, although its mechanism is currently unclear.

The two cases reported here suggest that acute cervical dystonia should be included in the spectrum of extrapyramidal adverse events of clebopride administration, and physicians who prescribe this drug should be aware of it.

Written informed consent was obtained from the videotaped patient (case ).

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Supplementary Materials

Supplementary Video. The patient shows increased muscle tone in the whole neck and torticollis to the left side (Supplementary Materials).


  1. J. Y. Hong, M. K. Sunwoo, J. S. Oh, J. S. Kim, Y. H. Sohn, and P. H. Lee, “Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging,” PLoS ONE, vol. 11, no. 6, Article ID e0157410, 2016. View at: Publisher Site | Google Scholar
  2. J. Einsiedel, K. Weber, C. Thomas, T. Lehmann, H. Hübner, and P. Gmeiner, “Stereocontrolled dopamine receptor binding and subtype selectivity of clebopride analogues synthesized from aspartic acid,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 19, pp. 3293–3296, 2003. View at: Publisher Site | Google Scholar
  3. P. Montagna, A. S. Gabellini, L. Monari, and E. Lugaresi, “Parkinsonian syndrome after long‐term treatment with clebopride,” Movement Disorders, vol. 7, no. 1, pp. 89-90, 1992. View at: Publisher Site | Google Scholar
  4. F. J. Jiménez‐Jiménez, F. Cabrera‐Valdivia, L. Ayuso‐Peralta, J. Tejeiro, A. Vaquero, and E. García‐Albea, “Persistent parkinsonism and tardive dyskinesia induced by clebopride,” Movement Disorders, vol. 8, no. 2, pp. 246-247, 1993. View at: Publisher Site | Google Scholar
  5. M. Ortí-Pareja, F. J. Jiménez-Jiménez, A. Vázquez et al., “Drug-induced tardive syndromes,” Parkinsonism & Related Disorders, vol. 5, no. 1-2, pp. 59–65, 1999. View at: Publisher Site | Google Scholar
  6. A. P. Sempere, S. Mola, and J. Flores, “Tardive dystonia following the administration of clebopride,” Rev Neurol, vol. 25, no. 148, 1997. View at: Google Scholar
  7. D. Bosco, M. Plastino, M. G. Marcello, P. Mungari, and A. Fava, “Acute hemifacial dystonia possibly induced by Clebopride,” Clinical Neuropharmacology, vol. 32, no. 2, pp. 107-108, 2009. View at: Publisher Site | Google Scholar
  8. W. Kim, K.-S. Lee, Y.-I. Kim, and J.-S. Kim, “Acute oculogyric crisis in a patient taking clebopride,” Internal Medicine, vol. 47, no. 6, pp. 551-552, 2008. View at: Publisher Site | Google Scholar
  9. F. López Rois, M. Conce Pico, J. Calvo Fernández, I. Novo, and M. Castro-Gago, “Simdrome extrapyramidal medicamentoso: A proposito de 22 observationes,” Anales Espanoles De Pediatria, vol. 26, no. 2, pp. 91–93, 1987. View at: Google Scholar
  10. G. A. Keepers, V. J. Clappison, and D. E. Casey, “Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes,” Archives of General Psychiatry, vol. 40, no. 10, pp. 1113–1117, 1983. View at: Publisher Site | Google Scholar
  11. M. Raja and A. Azzoni, “Novel antipsychotics and acute dystonic reactions,” The International Journal of Neuropsychopharmacology, vol. 4, no. 04, pp. 393–397, 2001. View at: Publisher Site | Google Scholar
  12. J. A. Domínguez-Morán, J. M. Callejo, L. C. Fernández-Ruiz, and J. C. Martínez-Castrillo, “Acute paroxysmal dystonia induced by fluoxetine,” Movement Disorders, vol. 16, no. 4, pp. 767–769, 2001. View at: Publisher Site | Google Scholar
  13. O. P. Dhakal, M. Dhakal, and D. Bhandari, “Domperidone-induced dystonia: A rare and troublesome complication,” BMJ Case Reports, Article ID A1389, 2014. View at: Publisher Site | Google Scholar
  14. U. Yis, D. Ozdemir, M. Duman, and N. Unal, “Metoclopramide induced dystonia in children: two case reports,” European Journal of Emergency Medicine, vol. 12, no. 3, pp. 117–119, 2005. View at: Publisher Site | Google Scholar
  15. F.-L. Tianyi, V. N. Agbor, and T. Njim, “Metoclopramide induced acute dystonic reaction: A case report,” BMC Research Notes, vol. 10, no. 1, 32 pages, 2017. View at: Publisher Site | Google Scholar

Copyright © 2017 Jin Kyo Choi and Jin Yong Hong. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.